en · de · es · fr · pt
ipamorelin-notes.peptides9000.com › Topic › Background And Structural Identity — Beginner to Advanced

Background And Structural Identity — Beginner to Advanced

By Editorial Desk · published 2026-01-20 · last reviewed 2026-03-09 · Topic

If you have been reading about selectivity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Ipamorelin Background and Receptor Pharmacology

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with C-terminal amide
Average massApproximately 711.9 DaValue derived from the formula
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and aqueous acetonitrileDissolution aided by acidic diluents
Common synonymsIpamorelin; NNC 26-0161Code name used in early reports

Handling, Stability and Analytical Verification

Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.

Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.

Related pages on this site

Further detail

=== King's Police Medal (KPM) === Bernard Kenneth Bonamy Jr., Assistant Commissioner of Police, Royal Bahamas Police Force. Theophilus Andrew Cunningham. Assistant Commissioner of Police, Royal Bahamas Police Force.

Immuno-ligation methods High-throughput multiplex assays allow for the simultaneous detection of multiple proteins and thus improve profiling capabilities. This is opening up avenues to even more clinical applications with increased precision and biology.

, the spreading slows down thus useful to set a prediction on the short-term trends. Also, it can be used to directly calculate the threshold population of vaccination/immunization for the herd immunity stage by setting

Sources: en.wikipedia.org

Supporting material

== Consequences == There are 3 levels of consequences: physiologic, intermediate, and clinical. The physiologic consequences include hypoxia, sleep fragmentation, autonomic nervous system dysregulation, or hyperoxia. The intermediate results regroup inflammation, pulmonary vasoconstriction, general metabolic dysfunction, oxidation of proteins and lipids, or increased adiposity. The clinical repercussions include pulmonary hypertension, accidents, obesity, diabetes, different heart diseases, and hypertension.

=== Example of sarcoma immunology research: the Immunological Constant of Rejection === When the immunological constant of rejection signature (ICR) was retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables; thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients' age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative/qualitative scores of immune response. ICR1 class was associated with a 59% increased risk of metastatic relapse when compared with ICR2-4 class. In multivariate analysis, ICR classification remained associated with metastasis-free survival, as well as pathological type and Complexity Index in Sarcomas (CINSARC) classification, suggesting independent prognostic value. ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. A robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.

=== Contamination === A 2011 survey of 33 supplements commercially available in Italy found that over 50% of them exceeded the European Food Safety Authority recommendations in at least one contaminant. The most prevalent of these contaminants was creatinine, a breakdown product of creatine also produced by the body. Creatinine was present in higher concentrations than the European Food Safety Authority recommendations in 44% of the samples. About 15% of the samples had detectable levels of dihydro-1,3,5-triazine or a high dicyandiamide concentration. Heavy metals contamination was not found to be a concern, with only minor levels of mercury being detectable. Two studies reviewed in 2007 found no impurities.'

Sources: en.wikipedia.org

Notes from published material

=== Background === Until after the Second World War the landlocked British possession of Southern Rhodesia was not developed as an indigenous African territory, but rather as a unique state that reflected its multiracial character. This situation made it different from other lands that existed under colonial rule, as many Europeans had arrived to make permanent homes, populating the towns as traders or settling to farm the most productive soils. In 1922, faced with the decision to join the Union of South Africa as a fifth province or accept nearly full internal autonomy, the electorate cast its vote against South African integration. In view of the outcome of the referendum, the territory was annexed by the United Kingdom on 12 September 1923. Shortly after annexation, on 1 October 1923, the first constitution for the new Colony of Southern Rhodesia came into force. Under this constitution, Southern Rhodesia was given the right to elect its own thirty-member legislature, premier, and cabinet—although the British government retained a formal veto over measures affecting natives and dominated foreign policy. Over the course of the next three decades, Southern Rhodesia experienced a degree of economic expansion and industrialisation almost unrivalled in sub-Saharan Africa. Its natural abundance of mineral wealth—including large deposits of chromium and manganese—contributed to the high rate of conventional economic growth.

The lesions occur as multiple cutaneous and subcutaneous nodules up to 4 cm diameter. They may disappear spontaneously, or regress and appear at new sites simultaneously. Topographically lesions may be found on the face, ears, nose, neck, trunk, extremities (including foot pads), perineum and scrotum. Treatment options in SH and CH. SH has proven to be a difficult and frustrating condition to treat. Consequently, many of the early cases were euthanized. Originally we treated dogs with Thymosin (derived from bovine thymus) because of reports of its effectiveness in human LCH cases. Some dogs appeared to respond to this, but not consistently. The original rationale for using thymosin was that SH was likely an immunoregulatory disorder and not cancer. In the majority of instances corticosteroid treatment is ineffective, although in some instances of CH (about 10% of cases), steroid administration is very effective in controlling lesions so steroids are worth trying in this disease given the expense of the alternatives. More recently we have had success with immuno-suppressive doses of Cyclosporin A or Leflunomide. These drugs are potent inhibitors of T cell activation and their ability to abrogate clinical disease gives further support for SH and CH being disorders of immune regulation. Treatment with these drugs is exorbitantly expensive and may be needed for life in dogs with continuously active disease, which usually is the case in advanced SH.

== History == Finasteride was the first 5-ARI to be introduced for medical use. It was marketed for the treatment of BPH in 1992 and was subsequently approved for the treatment of pattern hair loss in 1997. Epristeride was the second 5-ARI to be introduced and was marketed for the treatment of BPH in China in 2000. Dutasteride was approved for the treatment of BPH in 2001 and was subsequently approved for pattern hair loss in South Korea in 2009 and in Japan in 2015. The patent protection on finasteride and dutasteride has expired and both drugs are available as generic medications.

==== Saline implants ==== The saline breast implant—filled with saline solution (biological-concentration salt water 0.90% w/v of NaCl, ca. 300 mOsm/L.)—was first manufactured by the Laboratoires Arion company, in France, and was introduced for use as a prosthetic medical device in 1964. The contemporary models of saline breast implant are manufactured with thicker, room-temperature vulcanized (RTV) shells made of a silicone elastomer. The study In vitro Deflation of Pre-filled Saline Breast Implants (2006) reported that the rates of deflation (filler leakage) of the pre-filled saline breast implant made it a second-choice prosthesis for corrective breast surgery. Nonetheless, in the 1990s, the saline breast implant was the prosthesis most common device used for breast augmentation surgery in the United States, because of the U.S. FDA's restriction against the implantation of silicone-filled breast implants outside of clinical studies. Saline breast implants have enjoyed little popularity in the rest of the world, possessing negligible market share. The technical goal of saline-implant technology was a physically less invasive surgical technique for emplacing an empty breast implant device through a smaller surgical incision.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Has ipamorelin been approved for clinical use?

It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.

Why is selectivity emphasised in the literature?

Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.

What is ipamorelin classified as?

It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.

Network